Loomis, Sayles & Company
SPPI

Loomis, Sayles & Company’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Loomis, Sayles & Company’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-926
Closed -$4K – 1060
2016
Q4 		$4K Sell
926
-769
-45% -$3.23K ﹤0.01% 937
2016
Q3 		$8K Hold
1,695
– – ﹤0.01% 807
2016
Q2 		$11K Buy
+1,695
New +$12K ﹤0.01% 741

Other funds holding SPPI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Loomis, Sayles & Company's SPPI Position: Q1 2017 in Review

Loomis, Sayles & Company sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q1 2017, closing a stake of 926 shares — an estimated $4K sold.

Loomis, Sayles & Company first reported a position in SPPI in Q2 2016 and held it in 3 quarters. The position peaked at $11K in Q2 2016. 128 funds tracked by Wall St. Rank hold SPPI as of Q1 2017.

  • Loomis, Sayles & Company reported no remaining Spectrum Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 926 Spectrum Pharmaceuticals Inc shares in Q1 2017, an estimated $4K.
  • Loomis, Sayles & Company first reported a position in Spectrum Pharmaceuticals Inc in Q2 2016 and held it in 3 quarters.
  • Loomis, Sayles & Company's Spectrum Pharmaceuticals Inc position peaked at $11K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q1 2017.

Based on Loomis, Sayles & Company's 13F filing for Q1 2017, filed 12 May 2017.